In short
This article examines ongoing clinical trials investigating the use of MPS-213, a component of the cancer vaccine Tedopi (OSE2101), in treating various types of cancer. These trials aim to evaluate the safety and efficacy of MPS-213 as part of combination therapies or maintenance treatments for patients with advanced cancers, including non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
What is MPS-213?
MPS-213 is one of the active substances in TEDOPI, a cancer vaccine developed by OSE Immunotherapeutics. TEDOPI is a combination of 10 synthetically manufactured peptides, including MPS-213, designed to stimulate the immune system to fight cancer cells. This type of treatment is known as immunotherapy, which harnesses the body's own immune system to target and destroy cancer cells.
How Does MPS-213 Work?
As part of the TEDOPI vaccine, MPS-213 works by activating the body's T cells, which are a crucial component of the immune system. The vaccine is designed to target specific proteins found on cancer cells, helping the immune system recognize and attack these cells more effectively. This targeted approach aims to provide a more personalized treatment for cancer patients.
What Conditions Does MPS-213 Treat?
MPS-213, as a component of TEDOPI, is being studied for the treatment of several types of cancer, including:
- Non-Small Cell Lung Cancer (NSCLC): TEDOPI is being investigated for patients with advanced or metastatic NSCLC, particularly those who have developed resistance to previous immunotherapy treatments.
- Ovarian Cancer: Clinical trials are exploring the use of TEDOPI in patients with recurrent ovarian cancer.
- Pancreatic Cancer: Research is ongoing to evaluate TEDOPI's effectiveness in treating locally advanced or metastatic pancreatic ductal adenocarcinoma.
Clinical Trials Involving MPS-213
Several clinical trials are currently underway to assess the safety and efficacy of TEDOPI, which contains MPS-213:
- ARTEMIA Study: A phase 3 trial comparing TEDOPI to docetaxel in patients with metastatic NSCLC who have developed resistance to immune checkpoint inhibitors.
- TEDOVA Study: A phase 2 trial evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer.
- TEDOPAM Study: A phase 2 trial investigating TEDOPI in combination with FOLFIRI chemotherapy as a maintenance treatment for patients with advanced pancreatic cancer.
How is MPS-213 Administered?
TEDOPI, which contains MPS-213, is administered as an emulsion for injection. It is typically given through subcutaneous injection, which means it is injected just under the skin. The exact dosing schedule may vary depending on the specific clinical trial or treatment protocol.
Potential Side Effects
As with any medical treatment, TEDOPI may cause side effects. While specific information about MPS-213 side effects is not provided, common side effects of cancer vaccines and immunotherapies may include:
- Injection site reactions (redness, swelling, or pain)
- Flu-like symptoms (fever, chills, fatigue)
- Nausea or vomiting
- Muscle or joint pain
It's important to note that the safety profile of TEDOPI is still being evaluated in ongoing clinical trials.
Patient Eligibility for MPS-213 Treatment
Eligibility for treatment with TEDOPI, which contains MPS-213, may vary depending on the specific clinical trial or treatment protocol. However, some general criteria include:
- HLA-A2 Positive Status: Patients must have a specific genetic marker called HLA-A2 to be eligible for TEDOPI treatment.
- Cancer Type and Stage: Eligibility is typically limited to patients with specific types and stages of cancer, such as advanced NSCLC, recurrent ovarian cancer, or metastatic pancreatic cancer.
- Previous Treatments: Some trials focus on patients who have developed resistance to previous immunotherapy treatments or have received specific prior therapies.
- Overall Health Status: Patients must generally be in good overall health, with adequate organ function and a good performance status.
It's important for patients to discuss their eligibility for TEDOPI treatment with their healthcare provider, as they can provide the most up-to-date and personalized information based on individual medical history and current health status.